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Abstract
Background: Acute lower respiratory infections are the commonest cause of morbidity and potentially preventable
mortality in Indigenous infants. Infancy is also a critical time for post-natal lung growth and development. Severe
or repeated lower airway injury in very young children likely increases the likelihood of chronic pulmonary
disorders later in life. Globally, bronchiolitis is the most common form of acute lower respiratory infections during
infancy. Compared with non-Indigenous Australian infants, Indigenous infants have greater bacterial density in their
upper airways and more severe bronchiolitis episodes. Our study tests the hypothesis that the anti-microbial and
anti-inflammatory properties of azithromycin, improve the clinical outcomes of Indigenous Australian infants
hospitalised with bronchiolitis.
Methods: We are conducting a dual centre, randomised, double-blind, placebo-controlled, parallel group trial in
northern Australia. Indigenous infants (aged ≤ 24-months, expected number = 200) admitted to one of two
regional hospitals (Darwin, Northern Territory and Townsville, Queensland) with a clinical diagnosis of bronchiolitis
and fulfilling inclusion criteria are randomised (allocation concealed) to either azithromycin (30 mg/kg/dose) or
placebo administered once weekly for three doses. Clinical data are recorded twice daily and nasopharyngeal swab
are collected at enrolment and at the time of discharge from hospital. Primary outcomes are ‘length of oxygen
requirement’ and ‘duration of stay,’ the latter based upon being judged as ‘ready for respiratory discharge’. The
main secondary outcome is readmission for a respiratory illness within 6-months of leaving hospital. Descriptive
virological and bacteriological (including development of antibiotic resistance) data from nasopharyngeal samples
will also be reported.
Discussion: Two published studies, both involving different patient populations and settings, as well as different
macrolide antibiotics and treatment duration, have produced conflicting results. Our randomised, placebo-
controlled trial of azithromycin in Indigenous infants hospitalised with bronchiolitis is designed to determine
whether it can reduce short-term (and potentially long-term) morbidity from respiratory illness in Australian
Indigenous infants who are at high risk of developing chronic respiratory illness. If azithromycin is efficacious in
reducing the morbidly of Indigenous infants hospitalised with bronchiolitis, the intervention would lead to
improved short term (and possibly long term) health benefits.
Trial registration: Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12610000326099
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Worldwide, bronchiolitis is the most common acute
lower respiratory tract infection (ALRI) in infants[1-3].
In the Northern Territory (NT, Australia), ALRIs are
t h em o s tf r e q u e n tr e a s o nf o rh o s p i t a l i s a t i o no fy o u n g
children (aged <5-years). ALRIs are also the commonest
cause of preventable deaths in Indigenous infants (5
times that of non-Indigenous)[4]. Of ALRIs, bronchioli-
tis (with or without pneumonia) is the most frequent
reason for hospital admission in NT Indigenous infants
aged under 12-months[5]. Despite this heavy burden of
bronchiolitis in Indigenous infants, currently no pro-
spective studies have been published. Our retrospective
review of 101 infants hospitalised with bronchiolitis at
the Royal Darwin Hospital (Darwin, Northern Territory)
found that 33.7% of Indigenous infants were readmitted
within six-months of discharge from hospital[6]. As
most were retrieved from remote communities, the
impact of the illness, its costs and social dislocation
were likely to have been substantial.
Recurrent ALRIs are independently associated with
the development of bronchiectasis[7] and reduced pul-
monary function later in life[8]. Low birth weight and
pre-existing small lungs are important determinants of
future lung function, but there is increasing evidence
that events in early life are at least equally important
determinants of adult pulmonary dysfunction[8-10]. The
first few years of life are the most critical period[11].
Thus events such as severe ALRIs during this critical
period are likely to have long term effects.
Australia-wide, hospitalisation rates of respiratory dis-
orders among Indigenous Australians are second only to
those for renal dialysis[12]. Furthermore, we have pre-
viously documented that the severity of the hospitalised
ALRI episode, as determined by oxygen requirement
and duration of hospitalisation, was an independent risk
factor for subsequent bronchiectasis[7]. In the Northern
Territory (NT), bronchiectasis affects one in every 68
Indigenous children, far exceeding that of cystic fibrosis
(CF) in non-Indigenous Australian children (1 in 2857)
[13,14]. Thus, any intervention that reduces bronchiolitis
severity and/or risk of readmission for respiratory illness
in Indigenous infants may have both short term and
potential long term benefits in our setting.
Bronchiolitis is characterised by extensive inflamma-
tion of the airways accompanied by increased mucous
production and necrosis of airway epithelial cells. In
paediatrics, bronchiolitis is a clinical diagnosis charac-
terised by tachypnoea, wheeze and/or crepitations in
infants following a preceding upper respiratory illness
[1]. It is primarily caused by infection of the respiratory
epithelial cells by a variety of viruses, especially respira-
tory syncytial virus (RSV). Other viruses (adenovirus,
influenza, parainfluenza, human metapneumovirus,
rhinovirus) are also implicated and increasingly new
viruses are being detected in association with this illness
[15]. In addition, Mycoplasma pneumoniae and Chlamy-
dia species are recognised increasingly as important con-
tributors to the development of chronic lung disease and
altered lung maturation[16-19]. New treatable bacteria
such as Simkania negevensis (a Chlamydia-like microbe)
has been found in Canadian Inuit infants with bronchio-
litis[20]. There are no published data on the nature or
diversity of respiratory pathogens associated with
bronchiolitis in Indigenous Australians infants.
Typically anti-microbials are not recommended in the
routine management of bronchiolitis[1,21]. While there
are two RCTs on macrolides for bronchiolitis, the single
available RCT on a non-macrolide anti-microbial was a
negative study[22]. However in our setting, there are
several reasons why anti-microbials may reduce the
morbidity of hospitalised Indigenous infants with
bronchiolitis. Colonisation of nasopharynx with bacteria
is a known risk factor for childhood pneumonia[23].
Indigenous infants not only have colonised nasopharynx
very early in life (as early as aged 2-weeks), but the colo-
nisation is also dense with common respiratory bacterial
pathogens, notably Streptococcus pneumoniae, Haemo-
philus infleunzae and Moraxella catarrhalis[24].
Repeated micro-aspiration of nasopharyngeal secretions
heavily laden with pathogenic bacteria during ALRI may
overwhelm already compromised pulmonary defences,
increasing the risk of a secondary pneumonia or other
lower airway infection. Indeed, Indigenous infants are
more likely to receive antibiotics for an episode of pneu-
monia diagnosed during an admission for bronchiolitis
than non-Indigenous infants nursed in the same paedia-
tric unit[6].
Macrolides are a class of antibiotics containing a
macrocyclic lactone ring with excellent tissue penetra-
tion and antimicrobial activity against a broad range of
gram positive and gram negative bacteria, including
intracellular pathogens such as Chlamydia.T h o s ew i t h
a 14- or 15-membered lactone ring also have several
non-antimicrobial properties that have been studied
extensively in-vitro and in experimental models and, to
a lesser extent, in humans[25]. One of these effects is
modulation of the immune response. The immune mod-
ulating properties of macrolides make them attractive
candidates for treating inflammatory airways diseases.
The two published[26,27] placebo-controlled RCTs on
macrolides for RSV-bronchiolitis reported contradictory
results. In a small Turkish study of 21 hospitalised
infants with moderate to severe bronchiolitis, 3-weeks of
daily clarithromycin significantly reduced severity of ill-
ness (oxygen use, hospital stay) and risk of hospital
readmission for respiratory illness during the next 6
months[26]. However in another larger study involving
Chang et al. Trials 2011, 12:94
http://www.trialsjournal.com/content/12/1/94
Page 2 of 871 infants from the Netherlands, 3-days of azithromycin
was not efficacious in infants hospitalised with bronch-
iolitis[27]. The difference in outcomes seen in the two
trials may be related to the dose or length of treatment,
chance, or heterogeneity of the study populations.
Infants in Turkey are more likely to have concomitant
bacterial infection compared to an affluent European
group and moreover in Turkey, post-infectious child-
hood bronchiectasis remains an important health pro-
blem[28]. The populations also differed in age. The
European study included infants up to 24-months of
age, whereas the Turkish study involved only infants
aged <7-months[26,27]. Clearly, a well designed RCT on
the efficacy of macrolides to reduce the burden of
bronchiolitis in a population at high risk of acute and
chronic respiratory disease would be beneficial.
Aims of the study
Our primary research question is: Amongst hospitalised
Indigenous infants with bronchiolitis, does azithromycin
(compared to placebo) improve clinical outcomes
(length of stay in hospital and duration of oxygen sup-
plementation)? Our primary hypothesis is that: The
anti-microbial and anti-inflammatory properties of the
macrolide, azithromycin, will improve the clinical
outcomes of Indigenous infants hospitalised with
bronchiolitis.
Our secondary aims are:
2. To determine the effect of azithromycin on read-
missions into hospital within 6 months of treatment;
3. To assess the short-term impact of azithromycin on
macrolide resistance patterns of respiratory bacterial
pathogens in the nasopharynx; and
4. To describe the point prevalence and diversity of
respiratory viruses, Mycoplasma pneumoniae and Chla-
mydia species using sensitive molecular diagnostic
techniques.
Methods
Study design
We are conducting a parallel group, double-blind pla-
cebo RCT (with concealed allocation) to assess the
impact of additional treatment with azithromycin in
Indigenous infants admitted to two regional hospitals
(Darwin, Northern Territory and Townsville, Queens-
land) with bronchiolitis. Our study plan is summarised
in Figure 1.
Eligibility
The inclusion criteria are:
Indigenous infants with bronchiolitis
fulfilling inclusion criteria 
Informed consent
S
t
a
n
d
a
r
d
Baseline data, NPS-1
Twice daily clinical assessment 
Azithromycin Placebo
Day 0
d
i
s
e
d
 
m
a
n
a
g
e
m
e
n
t
 
o
f
m
e
d
i
c
a
Ready for Hospital Discharge, NPS-2
Azithromycin Placebo
Azithromycin Placebo
Day 7
Day 14
All primary and some
secondary outcomes obtained
f
b
r
o
n
c
h
i
o
l
i
t
i
s
 
o
t
h
e
r
 
t
h
a
t
i
o
n
s
Final clinical review
Study completion
y y
6 months
D21 secondary outcomes
Hospital readmission data
h
a
n
 
t
r
i
a
l
 
Day 21
Figure-1 Overall schematic study plan.
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Page 3 of 81. Indigenous infants (aged ≤ 24-months) admitted to
one of our hospitals (Darwin and Townsville) with a
clinical diagnosis of bronchiolitis. In the absence of an
international standardised diagnosis of bronchiolitis,
[29,30] the accepted Australian clinical diagnosis is used
(tachypnoea (respiratory rate ≥60/min in infants aged
<2-months, ≥50/min if 2-12 months, and >40/min if 13-
24 months), with wheeze or crackles);[31,32] and
2. Recruited and consented within 24-hours of presen-
tation to the hospital for the illness.
Exclusion criteria: admission into intensive care,
macrolide therapy contraindicated (e.g. liver dysfunction,
hypersensitivity), presence of diarrhoea (stools of
increased watery consistency and more than two stools
above usual stooling frequency), received macrolides (in
last 7-days), or clinical and radiological features consis-
tent with a primary diagnosis of pneumonia,[33] at time
of randomisation.
Recruitment
At each site, the site-specific study nurse visits the
wards twice daily to screen all newly admitted infants. A
standardised collection form is used to collect clinical
data (see below) and hospital outcomes associated with
the bronchiolitis episode. All infants are managed
according to a standardised protocol. This has been
used at the Royal Darwin Hospital since 2008. The pro-
tocol outlines when supplementary oxygen is prescribed
(Sp02<94%) and reduced, and when nasogastric feeds or
intravenous fluids are used. Enrolled infants may receive
additional therapies (other than macrolides) at the dis-
cretion of the attending paediatrician.
Intervention and follow up
If eligibility is fulfilled and after informed consent has
been obtained, the infant is randomised to receive either
a single, oral liquid dose of azithromycin syrup (30 mg
per kg) or an equivalent volume of placebo. Medication
is given within 24-hours of hospitalisation. Infants ran-
domised to the intervention arm of the study will
receive additional treatment doses of azithromycin syrup
(30 mg per kg) on day-7 and day-14. Those randomised
to the control arm receive an equivalent volume of the
placebo syrup. The later doses will be either supervised
by study nurses or administered by families with phone
support on the day the medication is due. Final clinical
follow up will occur in the local health clinic on day-21
(or closest available date from day 20 to 24).
Randomisation, allocation and blinding
The randomisation sequence was computer generated
and used permutated blocks (4 or 6 participants per
block). The allocation sequence is concealed at all times
throughout the study. The computer generation and
allocation were performed by a statistician, external to
the study team. Upon enrolment, an infant is assigned
to the next number on the appropriate stratified list.
Each unique number is assigned to one of the eight
treatment alphabets (see below). Treatment groups are
stratified by age (≤6o r> 6m o n t h s ) ,s i t e( D a r w i no r
Townsville) and requirement (yes or no) for oxygen at
point of randomisation. The importance of excluding
older children and stratifying at the 6 month age group
is well described[30,34]. A placebo medication ensures
that all children, carers, researchers, hospital staff, and
clinic staff are blinded to treatment group until analyses
of the data.
The placebo medication has been specifically manu-
factured by the Institute of Drug Technology (IDT)
Australia Limited (Melbourne, Vic) which has a similar
taste and colour to azithromycin. The azithromycin
medications were repackaged by IDT. Thus both the
azithromycin and placebo are in identical opaque bottles
and sealed with an aluminium foil. For both, equal
volumes of water are added using a syringe and needle
by punching the seal.
Eight alphabets (N, O, P, Q, R, S, T, U) were used for
the bottles of azithromycin and placebo medications (4
alphabets each). We used multiple alphabets rather than
sequential numbers on the bottles to allow storage of
extra bottles of trial medications in clinics for the day-7
and day-14 doses. This was necessary in the context of
our study setting (children mainly from remote Indigen-
ous communities), to enhance availability and adminis-
tration of trial medications once the child has been
discharged from the hospital.
Data collection
All data are recorded on standardised forms. Demo-
graphic information (age, gender, region, birth details,
smoke exposure, breast feeding, household size, etc) and
medical history are obtained from the primary care-
giver and the medical charts. The primary and second-
ary outcome measures (see below) are monitored twice
daily until the hospital admission’s end-point is reached
(ready for respiratory discharge, defined as >16-hours
without supplemental oxygen and infant is feeding well).
Clinical assessment data include oxygen requirement
and level, physiological measurements for clinical sever-
ity score (respiratory rate, accessory muscle use, degree
of wheeze),[27] other physiological measurement (tem-
perature, heart rate), requirement and duration of other
therapies required (intravenous fluids, nutritional sup-
port, antibiotics), ear examination findings (signs of sup-
puration) and subsequent pneumonia (diagnosed by the
independent treating ‘blinded’ paediatrician). In addition,
the results of routine investigations (full blood count
and chest radiographic findings) are recorded. On day-
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Page 4 of 821, the presence of cough, wheeze and auscultatory
abnormality on clinical review are documented. Adverse
effects (vomiting, diarrhoea, rash) are also documented.
Specimen collection
A single nasopharyngeal swab (NPS) specimen for
respiratory virus and other potentially important respira-
tory pathogen (M. pneumoniae, Chlamydia spp) testing
is collected from each subject at enrolment. In addition,
NPS is repeated before hospital discharge for bacterial
culture and antibiotic susceptibility testing, as per our
laboratory research protocol (see below)[35,36].
Laboratory methods
Bacteriology of NPS
Culturing, identifying and serotyping common respira-
tory bacteria from NPS is an established technique in
our laboratory at Menzies in Darwin[35]. Swabs are
stored in SMGGB at -80°C before being batch processed
for typical respiratory bacterial pathogens, notably H
influenzae and non-typeable H influenzae, M. catarrha-
lis and S. pneumoniae. Batches of swabs are thawed and
10 μL aliquots cultured overnight on selective media at
37°C in 5% CO2.G r o w t ho fS. pneumoniae, H. influen-
zae and M. catarrhalis is recorded and confirmed. Four
isolates each of S. pneumoniae and H. influenzae and
two isolates of M. catarrhalis per positive swab are
tested for anti-microbial resistance and stored[35,37]. S.
pneumoniae isolates are serotyped using the Quellung
method (antisera from Statens Serum Institute,
Denmark).
In addition to routine susceptibility testing using the
calibrated dichotomous susceptibility (CDS) disc diffu-
sion method, azithromycin minimum inhibitory concen-
tration (MIC) will be determined using Etest (AB
Biodisk, Sweden) if the azithromycin disc annulus is less
than 6 mm. For S. pneumoniae, the penicillin MIC is
determined for penicillin non-susceptible isolates (oxa-
cillin and/or penicillin disc annulus <6 mm) and for H.
influenzae, the ampicillin MIC is determined for isolates
if the ampicillin disc annulus is less than 6 mm. Inter-
pretive criteria (CSLI breakpoints) used for S. pneumo-
niae are penicillin non-susceptible MIC > 0.12 μg/mL,
azithromycin resistant MIC ≥ 2 μg/mL, and for H. influ-
enzae, ampicillin resistant MIC ≥ 4 μg/mL, azithromycin
resistant MIC > 4 μg/mL. Beta-lactamase activity will be
determined for H. influenzae and M. catarrhalis isolates.
Assessment for viruses and atypical bacteria
Our previous methods will be utilised[15,38,39]. NPS are
frozen at -80°C. Upon thawing nucleic acids will be
extracted from 0.2 ml of each NPS specimen using the
High Pure Viral Nucleic Acid kit (Roche Diagnostics,
Australia), according to the manufacturer’s instructions.
Mono-specific PCR and reverse transcriptase PCR (RT-
PCR) method will be used to detect Mycoplasma pneu-
moniae, coronaviruses, bocavirus and human metapneu-
movirus (hMPV), whereas multiplex PCR and RT-PCR
was used to detect adenovirus, parainfluenza (1, 2 3),
influenza (A and B), and respiratory syncytial virus
(RSV). All these methods have been previously validated
in our viral laboratory at the Royal Children’sH o s p i t a l ,
Brisbane.
End point
Participation is complete when day-21 outcomes have
been obtained. Other exit points are: intolerance to the
trial medications requiring withdrawal from study (as
deemed by the treating paediatrician who is not directly
connected to the study team).
Outcome measures
Primary outcomes
(i) Length of stay (LOS) for respiratory illness in hospi-
tal- defined as time from admission to time ‘ready for
discharge’ for respiratory care. ‘Ready for discharge’
means normoxic (Sp02 consistently >94% in air for >16-
hrs) and feeding adequately; and (ii) Duration of supple-
mental oxygen required. ‘Ready for discharge’ for
respiratory care differs from length of hospitalisation as
discharge from hospital may be delayed because of
social or transport factors especially in children from
remote communities.
Secondary clinical outcomes
The major secondary outcome is readmission for
respiratory illness (within 6-months of discharge from
hospital). Minor outcomes during hospitalisation: clini-
cal severity score,[27] additional use of antibiotics, and
episodes of suppurative otitis media and development of
pneumonia. The Day-21 outcomes are: presence of
cough, wheeze, abnormal auscultatory chest signs and
suppurative otitis media. We will also analyse all clinical
outcomes in the following pre-determined sub-groups:
(i) age ≤ 6-months; and (ii) presence of bacterial respira-
tory pathogens that are resistant to macrolide
antibiotics.
Secondary laboratory outcomes
(i) identification of respiratory viruses and bacterial
pathogens and (ii) antibiotic resistance to penicillin and
macrolides.
Sample size
We plan to enrol 200 Indigenous infants. In our retro-
spective study,[6] the mean LOS in Indigenous infants
with bronchiolitis at RDH was 96 (SD 24) hours. The
mean duration of supplemental oxygen requirement in
Indigenous infants with bronchiolitis was 36 (SD 14)
hours. For a mean difference of 24-hours in LOS
between groups (power = 90%, a =5 % )t h er e q u i r e d
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12-hour difference in supplemental oxygen requirement
is 30 per group. These are large effect sizes but more
conservative estimates thans e e ni nt h eT u r k i s hs t u d y
[26]. In that study,[26] the difference between groups
was 30-hrs for LOS and 31-hours for supplemental oxy-
gen requirement. Assuming similar effects, a sample size
of at least 100 in each sub-age group is also sufficient
for an a-priori subgroup analysis based on age (power of
90% and 2-tailed a of 5%). If the effects are smaller, we
will have an 80% power to detect a difference of 10-
hours in LOS in all infants and an 80% power to detect
a difference of 14-hours in LOS in the ≤6-months age
group. We do not believe that smaller benefits than this
would be sufficient to change clinical practice.
For the most important secondary outcome (readmis-
sion rate for a respiratory illness within 6-months of dis-
charge), the power of our study to detect a reduction
from 30% to 10% is 95% (5% significance). This is a
large effect but consistent with the reduction described
in the Turkish study (75% reduction)[26]. At 80% power
we will be able to detect a reduction in readmission
rates from 30% to 13%. For our other secondary out-
comes, accurate sample size estimations are not possible
given the lack of any relevant data.
Statistical analysis and reporting
Data will be reported and presented in accordance with
the updated CONSORT criteria[40]. Children will be
analysed according to allocation status (regardless of
subsequent management). An interim analysis is
planned and the data safety and monitoring committee
will determine if the study should be ceased should
superiority of azithromycin be identified after 70% of
sample size is achieved.
The primary outcomes (LOS and duration of supple-
mental oxygen requirement) will be compared between
infants receiving placebo or azithromycin using unpaired
Student’s T-tests or Mann-Whitney tests (depending on
normality of distribution). Although we expect randomi-
sation to equally distribute potential confounding factors
between each of the groups, we will examine the distri-
bution of known confounders between groups (eg. birth
weight, smoke exposure status in-utero and postnatal,
breast feeding, etc). Should baseline data differ between
groups, regression will be used to check that the pri-
mary outcomes are not affected by this chance finding.
An a-priori sub-analysis will compare infants aged ≤ 6-
months with those aged >6-months.
When examining the efficacy of azithromycin at redu-
cing readmission rate for respiratory illness (Secondary
Aim-2), the Odds Ratio (OR) between groups will be
calculated. The OR will also be used to compare addi-
tional antibiotic use between groups. The number
needed to treat (NNT) (for benefit), 95% CI will be
described if any significant differences are found. If sig-
nificant, NNT for harm will be calculated for adverse
events. For Secondary Aim-3 (short-term impact of azi-
thromycin on macrolide-resistance of pathogens in NPS
cultures): the proportions of children with penicillin-
non-susceptible S. pneumoniae and macrolide-resistant
H. influenzae spp and M. catarrhalis before and after
trial medications will be compared using ORs and 95%
CI. Descriptive data will be utilised for Secondary Aim-4
(point prevalence of respiratory viruses and other
respiratory pathogens).
Ethical approval
The protocol has been granted full ethical approval from
the respective Human Research Ethics Committees of all
the participating institutions [Department of Health and
Families (for Royal Darwin Hospital) and Menzies
School of Health Research (Darwin), and the Townsville
Hospital].
Discussion
Acute lower respiratory tract infections are the com-
monest cause of hospitalisation and potentially preven-
table deaths in Indigenous infants[4]. Bronchiolitis in
Indigenous infants is more severe than bronchiolitis in
non-Indigenous infants[6]. There are higher readmission
rates and an increased risk of ongoing respiratory mor-
bidity (including chronic suppurative lung disease) in
Indigenous infants[7,41]. This may be due to an
increased likelihood of recurrent infections and virus-
bacteria interactions from an early age (as early as aged
2-wks) along with heavy bacterial colonisation of the
nasopharynx[36]. Despite bronchiolitis being the most
common cause of ALRIs in infants resulting in hospitali-
sation, there are no published prospective studies of this
illness in Australian Indigenous infants. Two small clini-
cal trials have studied macrolides in bronchiolitis, but
with contradictory results. Our population setting is
more closely related to the Turkish study[26] where a
beneficial effect for macrolides was shown. This is in
contrast to the negative findings of the Dutch study[27]
in an affluent urban setting.
Our proposed double-blind RCT will determine if azi-
thromycin is an effective additional treatment in Indi-
genous infants hospitalised with bronchiolitis. It will
also determine whether in the ensuing 6 months it will
prevent hospital readmissions from respiratory illnesses,
which potentially reduces the likelihood of chronic lung
dysfunction[7] in this high-risk population. Azithromy-
cin was chosen over other macrolides because of its
prompt and potent anti-inflammatory effects as well as
its 30-40 hours half-life in children, which permits once
weekly dosing[42]. The possiblea n t i - v i r a le f f e c t si sa l s o
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current study is to monitor for antibiotic resistance in
potential respiratory bacterial pathogens colonising the
nasopharynx.
For the first time in this population, we will determine
the nature and diversity of respiratory viruses, Myco-
plasma, Chlamydia and Chlamydia-like species in asso-
ciation with cases of bronchiolitis requiring hospital
admission. The range of organisms includes newly dis-
covered viruses,[44] and treatable bacteria that may con-
tribute to chronic lung dysfunction. M. pneumoniae and
Chlamydia species are increasingly recognised as impor-
tant contributors to development of chronic lung disease
and altered lung maturation[16-19]. Our study addresses
a large clinical research gap for an important and com-
mon cause of hospitalisation in Indigenous infants. If
the intervention is successful, it would lead to improved
short term (and possibly long term) health benefits.
Conclusive results would produce changes to evidence-
based standard treatment guidelines in our region and
those produced for similar populations nationally and
internationally. Finally, the intervention would also offer
the possibility of preventing (or reducing) the high rates
of long-term respiratory dysfunction seen in Australian
Indigenous children and adults.
The rationale for our chosen outcome measures
Risk factors for bronchiectasis in Indigenous children
include recurrent hospitalisation for ALRIs and severity
of previous ARLIs (measured by duration of stay and
requirement for oxygen supplementation during hospita-
lisation)[7]. In the context of the high burden of
bronchiectasis in our setting, we considered that the
most important outcomes are LOS, requirement for
oxygen supplementation during hospitalisation and
readmission within a 6-month period. Length of hospi-
talisation is a common outcome measure in studies on
bronchiolitis. However in our setting, hospitalised chil-
dren often come from remote comunities and may have
multiple co-morbidities[33] that influences their dis-
charge. Thus we used LOS defined in accordance with
‘ready for respiratory discharge’.
Limitations of our study
Our study only addresses infants hospitalised for
bronchiolitis. The impact of variable presentation parti-
cularly that related to the potential influence of azithro-
mycin’s acute immune modulation effect is a limitation
of our study. However our study design minimises the
impact of variable presentation by: (a) standardising our
inclusion criteria, (b) limiting enrolment to within 24
hours of hospitalisation; (c) adopting a strategy (double
blind, placebo controlled, allocation concealed metho-
dology) that would theoretically distribute any effect
equally between groups. Additionally in the event that
differences in baseline data between groups are found,
we will use statistical methods (multivariate analysis) to
adjust as required.
In summary, given the very high burden of bronchioli-
tis in Indigenous infants (the age when lung growth is
most critical post-natally), and the association between
ALRI and future lung dysfunction, our RCT on azithro-
mycin in Indigenous Australian infants hospitalised with
bronchiolitis has the potential to have both short term
gains and a long-term benefit for reducing morbidity of
respiratory illness.
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